Hairloss discussion involves treatments like Minoxidil, Finasteride, and RU58841. Stemoxydine may be effective, but results may take at least 3 months due to hair cycle.
Hairloss treatments vary greatly in effectiveness and timelines, with no guaranteed results. Common treatments mentioned include finasteride, minoxidil, and RU58841.
Hairloss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
Hairloss discussion involves minoxidil, finasteride, and RU58841. Minoxidil non-responders may see results after adding stemoxydine due to increased enzyme presence.
A user with stage 1 hairloss is inquiring about the release date of GT20029, hoping to use it instead of Minoxidil and finasteride, as they believe it has better results. They want to know if it will be available in the next couple of years.
Hairloss treatment with Pyrilutamide, Minoxidil, and Finasteride showed improvement after 4 months. Shedding reduced, hair feels stronger and healthier, with no side effects.
Hairloss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
Hairloss treatments, including the use of Minoxidil and Finasteride, with a user sharing their 8-month update on progress made. Others have chimed in to provide encouragement and advice for continued treatment.
Hairloss discussion includes finasteride intolerance and questioning if Pyrilutamide is an alternative. Pyrilutamide not commercially available, but may be tolerable if approved since it's not a 5aR inhibitor.
Hairloss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.
Hairloss discussion involved Finasteride, Minoxidil, and RU58841. User experienced sudden shedding after 1.5 years of Finasteride and Minoxidil use, seeking advice.
Hairloss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
Hairloss treatments, such as minoxidil, finasteride, microneedling, ketoconazole shampoo and vitamins D3 and Omega 3, which appear to have been successful in regrowing hair on a user's temples that had been slick bald for 8-9 years.
Hairloss approaches: 1) using treatments like Minoxidil, Finasteride, RU58841, vitamins, and transplants, or 2) accepting hairloss, trying minimal treatments, and shaving head. Users share experiences and preferences between options.
The conversation discusses the lack of updates on GT20029 for hairloss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
Hairloss can begin in early adolescence and cause mental anguish. Treatments mentioned include eating cruciferous vegetables, engaging in physical activity, and maintaining scalp hygiene.
Hairloss discussion involving finasteride's side effects and effectiveness. Users shared mixed experiences, with some reporting side effects and others seeing positive results.
The conversation is about hairloss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.
The conversation is about the anticipated release timeline for a hairloss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.
Hairloss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
Hairloss treatments, with users discussing their experiences with both RU58841 and Pyrilutamide, noting that the latter has only recently become available but may yield better results in the long term.